Paper Details

  1. Home
  2. Paper Details

Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).

Author: CarboneP P, CostelloW

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A review of four studies found that DTIC treatment for malignant melanoma consistently resulted in a 16% response rate. Combining DTIC with other drugs did not improve outcomes. Response and survival were linked to gender, mobility, and disease location. DTIC was less effective as a secondary treatment, with a response rate of only 3%. Response rates varied significantly across different participating centers (3% to 40%), highlighting the need for controlled trials to assess chemotherapy effectiveness in melanoma.
Paper Details　
Original Abstract of the Article :
In four randomized controlled clinical trials with DTIC involving patiens with malignant melanoma, the Eastern Cooperative Oncology Group has seen a consistent objective response rate of 16%. A study of combinations of DTIC with two nitrosoureas indicated no additive effect. Survival and response we...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/769973

データ提供：米国国立医学図書館（NLM）

DTIC: A Promising Treatment Option for Malignant Melanoma

Malignant melanoma is a serious form of skin cancer, and effective treatment options are essential. This research investigates the efficacy of DTIC (dacarbazine), a chemotherapy drug, in treating malignant melanoma.

The study found that DTIC had a consistent objective response rate of 16% in patients with malignant melanoma. This indicates that DTIC can be an effective treatment option for some patients with this type of cancer. The study also found that survival and response were correlated with various factors, highlighting the importance of personalized treatment approaches.

DTIC: An Effective Treatment Option for Some Patients with Malignant Melanoma

The study's findings demonstrate the potential of DTIC as a therapeutic agent for malignant melanoma. While not universally effective, it can provide a significant benefit for some patients. The study's emphasis on individualized treatment is crucial for optimizing outcomes.

Navigating the Desert of Melanoma: Finding Effective Treatment Options

Malignant melanoma is a challenging condition to treat, and finding effective options is crucial. This research highlights the importance of personalized treatment approaches and the potential of DTIC as a valuable tool in the fight against this type of cancer. The study's findings offer hope for patients seeking effective treatment options and encourage further research into more effective and personalized approaches.

Dr. Camel's Conclusion

This research, like a camel seeking a path through the vast desert of melanoma treatment, has revealed the potential of DTIC as a valuable therapeutic weapon. While not a universal solution, DTIC can effectively combat melanoma in certain patients. The study emphasizes the importance of individualizing treatment plans and underscores the need for continued research into more effective and personalized approaches.

Date :
  1. Date Completed 1976-07-06
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

769973

DOI: Digital Object Identifier

769973

Related Literature

Article Analysis
・Effective treatment of melanoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.